Reinforcing its leadership in advanced cancer care, Sarvodaya Hospital, Faridabad, Delhi NCR, has become the first Theranostics and Nuclear Medicine center in India to introduce Terbium-161 PSMA therapy for prostate cancer. This groundbreaking milestone places the hospital at the forefront of comprehensive oncology services. It brings new hope to patients battling advanced metastatic castration-resistant or hormone-refractory prostate cancer.
Introducing CAR-T Cell Therapy for Blood Cancers
As reported by voiceofhealthcare, further elevating its commitment to innovation, the Sarvodaya Cancer Institute has launched CAR-T Cell therapy—one of the most advanced treatments for blood cancers such as leukemia, lymphoma, and multiple myeloma. By offering this cutting-edge immunotherapy, Sarvodaya Hospital now delivers holistic cancer care, from diagnosis to complex treatment, all within a single facility.
Precision Oncology Takes Center Stage
Dr. Swagat Dash, Head of Department and Senior Consultant, Nuclear Medicine, leads the initiative. He stated, “The launch of this revolutionary therapy in India brings renewed hope to patients fighting advanced prostate cancer.” Our team fully commits to delivering world-class cancer care in this defining moment for precision oncology.”
Redefining Complete Cancer Care
Echoing this vision, Dr. Dinesh Pendharkar, Director of Sarvodaya Cancer Institute, added, “At Sarvodaya Hospital, we are dedicated to evidence-based treatment approaches that improve patient outcomes. Being the first in India to offer Terbium-161 PSMA therapy reflects our focus on next-generation cancer solutions. By integrating both CAR-T Cell therapy and Theranostics, we are reshaping what complete cancer care truly means.”
Conclusion
With these latest advancements, Sarvodaya Hospital continues to set new benchmarks in oncology. It reaffirms its position as a trailblazer in cancer care innovation.